BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol. 2004;74:361-366. [PMID: 15332287 DOI: 10.1002/jmv.20185] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32:1535-1542. [PMID: 22882650 DOI: 10.1111/j.1478-3231.2012.02859.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
3 Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res 2010;85:512-9. [PMID: 20034521 DOI: 10.1016/j.antiviral.2009.12.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
4 Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009;53:2762-72. [PMID: 19433559 DOI: 10.1128/AAC.00130-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Peng XM, Gu L, Huang YS, Ma HH, Xie QF, Li G, Gao ZL. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR. J Virol Methods 2005;128:168-75. [PMID: 15950294 DOI: 10.1016/j.jviromet.2005.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
6 Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84:207-216. [PMID: 22170539 DOI: 10.1002/jmv.23182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
7 Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatol 2013;2013:130384. [PMID: 27335823 DOI: 10.1155/2013/130384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 2012;84:217-222. [PMID: 22170540 DOI: 10.1002/jmv.23191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
10 Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, Aghakhani A. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. Int J Infect Dis. 2008;12:252-255. [PMID: 17954033 DOI: 10.1016/j.ijid.2007.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
11 Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
12 Choi YJ, Kim HS, Lee SH, Park JS, Nam HS, Kim HJ, Kim CJ, Jeong DJ, Park KS, Baek KA. Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance. Arch Virol 2011;156:1517-24. [PMID: 21594598 DOI: 10.1007/s00705-011-1019-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
13 Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21:1783-1788. [PMID: 17074014 DOI: 10.1111/j.1440-1746.2006.04567.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
14 Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat 2010;17:23-7. [PMID: 19566788 DOI: 10.1111/j.1365-2893.2009.01149.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
15 Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57:508-514. [PMID: 22659518 DOI: 10.1016/j.jhep.2012.04.037] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 10.9] [Reference Citation Analysis]
16 Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, Zhong Y, Zhao J, Xu D. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol. 2010;48:270-274. [PMID: 20580309 DOI: 10.1016/j.jcv.2010.05.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
17 Lee SY, Choi MS, Lee D, Lee JH, Koh KC, Paik SW, Yoo BC. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J Korean Med Sci 2005;20:433-7. [PMID: 15953865 DOI: 10.3346/jkms.2005.20.3.433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
18 Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
19 França P, Coelho H, Brandão C, Segadas J, Quintaes R, Carrilho F, Ono-nita S, Mattos A, Tovo C, Gouvea V, Sablon E, Vanderborght B. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. Braz J Med Biol Res 2007;40:1605-14. [DOI: 10.1590/s0100-879x2006005000169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res. 2010;40:125-134. [PMID: 19788696 DOI: 10.1111/j.1872-034x.2009.00565.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol. 2007;39:149-152. [PMID: 17442615 DOI: 10.1016/j.jcv.2007.03.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
22 Tan YW, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis 2012;16:250-5. [PMID: 22729192 [PMID: 22729192 DOI: 10.1016/s1413-8670(12)70319-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
23 Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]